ArticleBMC gastroenterology2026
The prognostic effect of dual
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGastrointestinal neuroendocrine neoplasms (GI-NENs) exhibit heterogeneity in biological behavior, making it difficult to predict prognosis. We established the P Grade based on 68Ga-DOTANOC and 18F-FDG PET dual scans and evaluated the prognostic significance in patients with metastatic GI-NENs.
methodsThe P Grade was categorized based on SSTRI/FDG uptake into P1 (DOTANOC positive/FDG negative), P2 (DOTANOC positive/FDG positive), and P3 (DOTANOC negative/FDG positive). Patients would be classified into P grades based on dual scan. results. Then they were divided into medical treatment and surgical group. The correlation of P Grade with progression-free survival (PFS) and overall survival (OS) was evaluated using Kaplan-Meier analysis, and performed univariate and multivariate analyzes of relevant clinicopathological variables with PFS and OS.
resultsTwo hundred forty-three patients with metastatic GI-NENs were enrolled. P Grade exhibited notable statistical significance with OS and PFS in overall cohort on univariate and multivariate analysis (all p < 0.01). In surgery group, P Grade demonstrated independent predictive value for OS and PFS (all p < 0.01). In medical treatment group, P Grade demonstrated predictive value for PFS (all p < 0.01) and predicted OS (univariate P3vsP1, p < 0.01). Additional predictors of OS and PFS included WHO grade, age at diagnosis, location of primary site, sex and extrahepatic disease, they all had statistical significance with OS or PFS (p < 0.05) except sex factors.
conclusionOur cohort study demonstrates that P Grade obtained by combining 68Ga-DOTANOC and 18 F-FDG PET is a significant prognostic indicator for patients with metastatic GI-NENs, regardless of whether received medical treatment or surgical resection of the primary site. This will bring a new predictive tool to clinical practice and be applicable to patients with different treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.